Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
Recent updates in the second-line treatment of patients with metastatic colorectal cancer (mCRC) have indicated the benefit of adding aflibercept (plus FOLFIRI) after an oxaliplatin-containing regimen (with or without bevacizumab) or a bevacizumab-containing regimen after progression on a different bevacizumab-containing regimen. This has led some oncologists to compare the trials and equate the drugs, with the assumption that they confer equal efficacy, but the background of this must be adequately assessed before reaching this conclusion. In fact, the publication of these trial results has left oncologists with much to consider for their mCRC patients who will eventually progress on a first-line chemotherapy/bevacizumab regimen. The author comments on this issue and emphasizes the need for additional research into antiangiogenic biomarkers to identify patients who are likely to respond to one drug more than another.
Experimental Therapeutics Program, Tufts University School of Medicine , 800 Washington Street, Suite 7S-7099, Boston, MA 02111 , USA +1 617 636 8077 ; +1 617 636 7060 ; WSaif@tuftsmedicalcenter.org.
Muhammad Wasif
MW
Saif
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology*; D018572:Disease-Free Survival; D004311:Double-Blind Method; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D018579:Patient Selection; D000072483:Placenta Growth Factor; D011257:Pregnancy Proteins / Q000037:antagonists & inhibitors; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000494:pharmacology / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use; D016879:Salvage Therapy / Q000379:methods*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D042561:Vascular Endothelial Growth Factor B / Q000037:antagonists & inhibitors; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000037:antagonists & inhibitors / Q000737:chemistry; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors / Q000737:chemistry
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D009363:Neoplasm Proteins; D009944:Organoplatinum Compounds; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; C467485:VEGFB protein, human; D042461:Vascular Endothelial Growth Factor A; D042561:Vascular Endothelial Growth Factor B; D000077150:Oxaliplatin; D000072483:Placenta Growth Factor; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin